Non-small cell lung cancer patient with a rare UGP2-ALK fusion protein responded well to alectinib: a case report

被引:0
|
作者
Chen, Liulin [1 ]
Chu, Daifang [1 ]
Li, Wangping [1 ]
Zhang, Haitao [1 ]
机构
[1] AF Mil Med Univ, Tangdu Hosp, Dept Resp & Crit Care Med, 569 Xinsi Rd, Xian 710038, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
alectinib; ALK fusion; non; small; cell lung cancer; uridine diphosphate-glucose pyrophosphorylase 2; MECHANISMS;
D O I
10.1097/CAD.0000000000001531
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several rare anaplastic lymphoma kinase (ALK) fusions have been identified in patients with non-small cell lung cancer (NSCLC); however, their treatment is not currently uniform. alectinib has been commonly used to treat rare ALK fusions in patients with NSCLC. This is the first study to report the occurrence of a uridine diphosphate-glucose pyrophosphorylase 2 (UGP2)-ALK fusion in a patient with NSCLC. The patient, who was hospitalized because of shortness of breath lasting 20 days, showed hydrothorax of the left lung under a computerized tomography chest scan. Pathological histology revealed lung adenocarcinoma in the patient. The UGP2-ALK mutation was found by next-generation sequencing. Subsequently, the patient was administered alectinib, and thereafter, the tumor lesion was observed to gradually shrink over the follow-up period. Progression-free survival reached 10 months as of the follow-up date, with no adverse events detected. This case report provides valuable insights into the clinical management of NSCLC patients with UGP2-ALK fusions. Moreover, alectinib is confirmed to be an appropriate therapeutic agent for such patients.
引用
收藏
页码:97 / 100
页数:4
相关论文
共 50 条
  • [1] Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient A case report
    Thomas, Quentin Dominique
    Pautas, Marie
    Guilhaume, Marie-Noelle
    Fiteni, Frederic
    Ge, Tony
    Girard, Nicolas
    [J]. MEDICINE, 2021, 100 (43) : E27611
  • [2] Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report
    Sun, Kunyan
    Nie, Ligong
    Nong, Lin
    Cheng, Yuan
    [J]. THORACIC CANCER, 2021, 12 (12) : 1927 - 1930
  • [3] Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib
    Nakanishi, Yoko
    Masuda, Shinobu
    Iida, Yuko
    Takahashi, Noriaki
    Hashimoto, Shu
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (12) : E202 - E204
  • [4] A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature
    De Smedt, Fabian
    Dessy, Frederique
    Carestia, Luciano
    Baldin, Pamela
    Nana, Frank Aboubakar
    Clapuyt, Philippe
    Boon, Veronique
    Amant, Frederic
    Gziri, Mina Mhallem
    [J]. ONCOLOGY LETTERS, 2023, 25 (02)
  • [5] A novel intergenic region ALK fusion is targetable by alectinib in a non-small cell lung cancer patient with brain metastasis
    Cheng, Wanwan
    Qian, Chunfa
    Zhang, Haitao
    Meng, Qi
    Yin, Jiani C.
    Fang, Shencun
    [J]. ANTI-CANCER DRUGS, 2022, 33 (10) : 1182 - 1185
  • [6] New fusion gene PURA-ALK in patient with non-small cell lung cancer: case report
    Saskova, B.
    Pivovarcikova, K.
    Svajdler, M.
    Vanecek, T.
    [J]. VIRCHOWS ARCHIV, 2018, 473 : S318 - S318
  • [9] Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
    Hu, Yan
    Ren, Siying
    Wang, Ruoyao
    Han, Wei
    Xiao, Peng
    Wang, Li
    Yu, Fenglei
    Liu, Wenliang
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [10] Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
    Misawa, Kazuhito
    Nakamichi, Shinji
    Iida, Hiroki
    Nagano, Atsuhiro
    Mikami, Erika
    Tozuka, Takehiro
    Matsumoto, Masaru
    Miyanaga, Akihiko
    Noro, Rintaro
    Kubota, Kaoru
    Yamaguchi, Hiroki
    Seike, Masahiro
    [J]. ONCOTARGETS AND THERAPY, 2023, 16 : 65 - 69